SBIR-STTR Award

Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step in the recruitment of white blood cells to sites of inflammation. Vasoocclusion is precipitated by a P- selectin-mediated adhesion of sickled red cells and leukocytes. These cells bind to and block blood vessels precipitating painful crises, a hallmark of the disease. In preclinical studies in sickle cell models, administration of an antibody to P-selectin prevents vasoocclusion. The major aims of this proposal are the development of pharmacokinetic, pharmacodynamic, and immunogenicity assays to support an animal toxicology study and a Phase I/II trial in patients with sickle cell disease. In Phase 1 of this Fast Track Proposal, an ex vivo pharmacodynamic (PD) assay will be developed to measure the ability of a humanized antibody to P-selectin to block adhesion of monocytes to activated platelets using human/primate serum. The assay will allow us to establish a surrogate marker of drug activity. A pharmacokinetic (PK) ELISA based assay will be developed to measure the concentration of the humanized antibody in blood. This assay will allow us to monitor blood levels of the P-selectin antibody in primate and human studies. An immunogenicity assay will be developed to monitor the formation of human anti-humanized antibodies (HAHA) in human clinical studies. A primate safety/toxicity study will be conducted in a dose ranging study in cynomolgus monkey (Macaca fascicularis) to assess safety, toxicity, PK, PD of the humanized anti-P selectin antibody. In Phase 2 of this proposal a Phase I/II clinical study will be conducted in sickle cell patients to assess safety and the PK, PD and immunogenicity of a humanized antibody to P-selectin. The primary goal of the proposed study is to characterize the antibody prior to commencing a Phase II chronic dosing trial. The overarching goal of our program is to develop and commercialize a humanized antibody to P-selectin to treat vasoocclusive crisis in sickle cell patients. In doing so we are addressing a critical unmet medical need for a rare, debilitating orphan disease which currently has no effective approved treatment.

Public Health Relevance:
This proposal supports development of a humanized antibody to P-selectin to treat vasoocclusive crisis in sickle cell patients. Sickle cell disease is an inherited blood disorder that affects over 70,000 persons, primarily African-Americans, in the U.S. The drug being developed addresses a critical unmet medical need for a rare, debilitating orphan disease which currently lacks an effective treatment.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step in the recruitment of white blood cells to sites of inflammation. Vasoocclusion is precipitated by a P- selectin-mediated adhesion of sickled red cells and leukocytes. These cells bind to and block blood vessels precipitating painful crises, a hallmark of the disease. In preclinical studies in sickle cell models, administration of an antibody to P-selectin prevents vasoocclusion. The major aims of this proposal are the development of pharmacokinetic, pharmacodynamic, and immunogenicity assays to support an animal toxicology study and a Phase I/II trial in patients with sickle cell disease. In Phase 1 of this Fast Track Proposal, an ex vivo pharmacodynamic (PD) assay will be developed to measure the ability of a humanized antibody to P-selectin to block adhesion of monocytes to activated platelets using human/primate serum. The assay will allow us to establish a surrogate marker of drug activity. A pharmacokinetic (PK) ELISA based assay will be developed to measure the concentration of the humanized antibody in blood. This assay will allow us to monitor blood levels of the P-selectin antibody in primate and human studies. An immunogenicity assay will be developed to monitor the formation of human anti-humanized antibodies (HAHA) in human clinical studies. A primate safety/toxicity study will be conducted in a dose ranging study in cynomolgus monkey (Macaca fascicularis) to assess safety, toxicity, PK, PD of the humanized anti-P selectin antibody. In Phase 2 of this proposal a Phase I/II clinical study will be conducted in sickle cell patients to assess safety and the PK, PD and immunogenicity of a humanized antibody to P-selectin. The primary goal of the proposed study is to characterize the antibody prior to commencing a Phase II chronic dosing trial. The overarching goal of our program is to develop and commercialize a humanized antibody to P-selectin to treat vasoocclusive crisis in sickle cell patients. In doing so we are addressing a critical unmet medical need for a rare, debilitating orphan disease which currently has no effective approved treatment.

Public Health Relevance:
This proposal supports development of a humanized antibody to P-selectin to treat vasoocclusive crisis in sickle cell patients. Sickle cell disease is an inherited blood disorder that affects over 70,000 persons, primarily African-Americans, in the U.S. The drug being developed addresses a critical unmet medical need for a rare, debilitating orphan disease which currently lacks an effective treatment.

Thesaurus Terms:
4-Amino-10-Methylfolic Acid;4-Amino-4-Deoxy-10-Methylpteroyl-L-Glutamic Acid;Address;Adhesions;Affect;Affinity;African American;Afro American;Afroamerican;Animals;Antibodies;Assay;Binding;Binding (Molecular Function);Bioassay;Biologic Assays;Biological Assay;Bizzozero's Corpuscle/Cell;Black Populations;Black Or African American;Blood;Blood Diseases;Blood Platelets;Blood Serum;Blood Vessels;Blood Erythrocyte;Blood Leukocyte;Blood Monocyte;Blood Normocyte;Cd62p Antigens;Cell Culture Techniques;Cell Line;Cell Lines, Strains;Cell Model;Cellline;Cells;Cellular Model;Chronic;Clinical;Clinical Research;Clinical Study;Clinical Trials;Clinical Trials, Phase Ii;Clinical Trials, Unspecified;Contracting Opportunities;Contracts;Crab-Eating Macaque;Data;Deetjeen's Body;Development;Disease;Disorder;Dose;Drug Kinetics;Drugs;Elisa;Enzyme-Linked Immunosorbent Assay;Erythrocytes;Erythrocytic;Gmp-140;Goals;Grant;Hayem's Elementary Corpuscle;Hb Ss Disease;Hbss Disease;Hematologic Diseases;Hematological Disease;Hematological Disorder;Hemoglobin S Disease;Hemoglobin Sickle Cell Disease;Hemoglobin Sickle Cell Disorder;Hereditary;Human;Human, General;Inflm;Iv Drip;In Vitro;Inflammation;Inflammatory;Inherited;Intravenous Drip;Intravenous Infusion;L-Glutamic Acid, N-(4-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-;Lecam-3;Lead;Leukocyte Rolling;Leukocytes;Mab Therapeutics;Macaca Fascicularis;Mammalian Cell;Mammals, Primates;Man (Taxonomy);Man, Modern;Marrow Erythrocyte;Marrow Leukocyte;Marrow Monocyte;Marrow Platelet;Measures;Mediating;Medical;Medication;Methotrexate;Methotrexate Methylaminopterin;Methotrexatum;Metotrexato;Molecular Interaction;Monitor;Monkey, Crab-Eating;Monkey, Cynomolgus;Orphan Disease;P-Selectin;Pain;Painful;Patients;Pb Element;Persons;Pharmaceutic Preparations;Pharmaceutical Agent;Pharmaceutical Preparations;Pharmaceuticals;Pharmacodynamics;Pharmacokinetics;Pharmacologic Substance;Pharmacological Substance;Pharmacology;Pharmacology And Toxicology;Phase;Phase 2 Clinical Trials;Phase I/Ii Trial;Phase Ii Clinical Trials;Platelet Alpha-Granule Membrane Protein;Platelets;Prevention;Primates;Programs (Pt);Programs [publication Type];Property;Property, Loinc Axis 2;Qualifying;Red Blood Cells;Red Cell;Red Blood Corpuscule;Red Cell Of Marrow;Reticuloendothelial System, Blood;Reticuloendothelial System, Erythrocytes;Reticuloendothelial System, Leukocytes;Reticuloendothelial System, Platelets;Role;Safety;Sampling;Serum;Sickle Cell;Sickle Cell Anemia;Site;Specificity;Surrogate Markers;Testing;Therapeutic;Therapeutic Monoclonal Antibodies;Thrombocytes;Toxic Effect;Toxicities;Toxicology;White Blood Cells;White Cell;Work;Antibody Engineering;Base;Black American;Blood Corpuscles;Blood Disorder;Cell Bank;Clinical Investigation;Cultured Cell Line;Design;Designing;Disease/Disorder;Drepanocyte;Drip Infusion;Drug/Agent;Effective Therapy;Heavy Metal Pb;Heavy Metal Lead;Humanized Antibody;Humanized Monoclonal Antibodies;Immunogenic;Immunogenicity;In Vivo;Innovate;Innovation;Innovative;Intravenous Administration;Monocyte;New Therapeutics;Next Generation Therapeutics;Non-Human Primate;Nonhuman Primate;Novel Therapeutics;Phase 2 Study;Phase 2 Trial;Phase Ii Trial;Preclinical Study;Prevent;Preventing;Programs;Protocol, Phase Ii;Public Health Relevance;Response;Safety Study;Sickle Rbc;Sickle Cell Disease;Sickle Disease;Sickle Erythrocyte;Sickle Red Blood Cell;Sicklemia;Sickling;Social Role;Study, Phase Ii;Thrombocyte/Platelet;Vascular;Vein Infusion;White Blood Cell;White Blood Corpuscle